Brief: Madrigal Pharmaceuticals Completes Enrollment Of Clinical Outcomes Study Of Resmetirom In Patients With Compensated Nash/Mash Cirrhosis
21/10/2024 16:26
Oct 21 (Reuters) - Madrigal Pharmaceuticals Inc
MDGL.O :
* MADRIGAL PHARMACEUTICALS COMPLETES ENROLLMENT OF CLINICAL
OUTCOMES STUDY OF RESMETIROM IN PATIENTS WITH COMPENSATED
NASH/MASH CIRRHOSIS
Source text for Eikon: ID:nGNX75GYHp
Further company coverage: MDGL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Madrigal Pharmaceuticals
See all newsBrief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule
Madrigal Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Madrigal Pharmaceuticals Q2 revenue rises 71% on Rezdiffra demand
U.S. RESEARCH ROUNDUP-Boeing, Coca-Cola, PayPal
Brief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)